Partnership Aims to Personalize Cancer Care Tailored to the Needs of Southeast Asian Population to Provide Better Individualized Care SINGAPORE , June 18, 2024 /PRNewswire/ -- To increase patient access to affordable, advanced genomic testing for cancer in Singapore , Thermo Fisher Scientific Inc., the world leader in serving science, the National University Hospital, Singapore (NUH), and Mirxes, a Singapore -headquartered RNA technology company, signed a Memorandum of Understanding (MoU) agreement on Friday, 14 June 2024 . The agreement formalizes the commitment to collaborate, develop and clinically validate advanced, next-generation sequencing (NGS) genomic testing solutions and cancer research tailored specifically to address the needs of the Southeast Asian population.
There is limited access to affordable genomic testing in cancer, which has been a challenge in many countries across Southeast Asia . Local access to rapid NGS testing in cancer allows healthcare providers to select the most appropriate therapy for individualized patients. "NUH's deep clinical expertise combined with the cutting-edge advancements of biotechnology capabilities and research holds immense promise for the future of cancer care," said Associate Professor Tan Soo Yong , Head & Senior Consultant, Department of Pathology, NUH.
"This collaborative approach will empower us to refine early detection methods and deliver even more precise diagnoses and treatments, propelling us towards optimized clinic.
